Quick Answer
Enliven Therapeutics, Inc. reported Net Income of -$103.69 million for fiscal year 2025.
Enliven Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$103.69M | -16.5% |
| 2024 | -$89.02M | -24.4% |
| 2023 | -$71.58M | -90.1% |
| 2022 | -$37.66M | +26.7% |
| 2021 | -$51.38M | -24.2% |
| 2020 | -$41.36M | -76.3% |
| 2019 | -$23.46M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$20.15M | +13.0% | +20.5% |
| June 30, 2025 | -$25.34M | -27.0% | +11.2% |
| March 31, 2025 | -$28.54M | -25.5% | -23.3% |
| September 30, 2024 | -$23.16M | -11.5% | -16.1% |
| June 30, 2024 | -$19.95M | -19.3% | +12.3% |
| March 31, 2024 | -$22.74M | -54.4% | -9.5% |
| September 30, 2023 | -$20.77M | -96.8% | -24.2% |
| June 30, 2023 | -$16.72M | -88.1% | -13.6% |
- Enliven Therapeutics, Inc. showed a decrease of -16.5% in Net Income compared to the prior fiscal year.
- Over the 2019–2025 period, Enliven Therapeutics, Inc.’s net income has declined by 341.9% (from -$23.46 million to -$103.69 million).
- The most recent figure is from Enliven Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: